<DOC>
	<DOCNO>NCT00044538</DOCNO>
	<brief_summary>Lung cancer among common cancer world incidence continue increase . Chemotherapy patient Non-Small Cell Lung Cancer ( NSCLC ) investigation several decade several new drug activity NSCLC identify . These include taxanes , among commonly use class chemotherapy agent clinical oncology today . The usefulness taxanes limit development tumor resistance agent . This phase II trial BAY 59-8862 conduct determine anti-tumor efficacy BAY 59-8862 taxane-resistant NSCLC .</brief_summary>
	<brief_title>Evaluation BAY 59-8862 Taxane Resistant Non-Small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Measurable disease define presence least one measurable lesion Patients must receive least 3 week continuous therapy Taxane patient must subsequently develop progressive disease either treatment within 6 month treatment Life expectancy least 12 week Adequate bone marrow , liver kidney function Excluded medical condition like : preexisting neuropathy , active heart diseases ischemia , serious infection , HIV infection , chronic hepatitis B C ; brain metastasis , seizure , hypersensitivity taxanes , organ transplant , previous cancer exclude therapy medication , previous concomitant : anticancer chemotherapy immunotherapy study within 4 week prior study entry ; two prior anticancer chemotherapy regimens ; radiotherapy study within 4 week prior study entry ; bone marrow transplant . others : pregnant breastfeeding patient ; men woman enrol trial must use adequate barrier birth control measure course trial ; substance abuse , medical , psychological social condition may interfere patient 's participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Taxane</keyword>
	<keyword>Lung cancer , non-small cell</keyword>
	<keyword>NSCLC</keyword>
</DOC>